Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5675991 | 0.80 | ALDH1A1 (0.48) | ALDH1A1EPHX2CYP3A4CYP2C19HTT | |
| SCHEMBL5679996 | 0.77 | HSD11B1 (0.46) | ALDH1A1 | |
| SCHEMBL5675925 | 0.74 | ALDH1A1 (0.53) | ALDH1A1EPHX2HSD17B10HTT | |
| SCHEMBL22185943 | 0.68 | ALDH1A1 (0.73) | ALDH1A1EPHX2CYP3A4CYP2C19 | |
| SCHEMBL24201206 | 0.66 | ALDH1A1 (0.45) | ALDH1A1EPHX2HSD17B10CYP3A4CYP2C19 | |
| SCHEMBL3456910 | 0.65 | ALDH1A1 (1.00) | ALDH1A1 | |
| SCHEMBL5677302 | 0.61 | MEN1 (0.34) | ALDH1A1EPHX2 | |
| SCHEMBL24201205 | 0.61 | ALDH1A1 (0.51) | ALDH1A1EPHX2CYP3A4CYP2C19 | |
| SCHEMBL31529425 | 0.60 | EPHX2 (0.69) | ALDH1A1EPHX2CYP3A4CYP2C19HTT | |
| SCHEMBL31276295 | 0.59 | EPHX2 (0.72) | ALDH1A1EPHX2CYP3A4CYP2C19HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1497268-A4 | NITRIC OXIDE DONORS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2006-01-18 | — | — | EP | disclosed |
| EP-1497268-A2 | NITRIC OXIDE DONORS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| US-20030203915-A1 | Nitric oxide donors, compositions and methods of use related applications | NICOX S.A. (FR) | 2003-10-30 | — | — | US | disclosed |
| WO-2003086282-A2 | NITRIC OXIDE DONORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203915-A1 | Nitric oxide donors, compositions and methods of use related applications | NOS1, NOS2, NOS3 | ALDH1A1 507/4885EPHX2 671/4885GAA 3977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.